Artelo Biosciences's EPS (Basic) for the
three
months ended in Mar. 2024 was $0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00.
During the past 3 years, the average EPS without NRIGrowth Rate was 43.90% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 38.60% per year.
During the past 10 years, Artelo Biosciences's highest 3-Year average EPS without NRI Growth Rate was 45.10% per year. The lowest was -387.00% per year. And the median was -74.20% per year.
Artelo Biosciences Earnings per Share (Diluted) Historical Data
The historical data trend for Artelo Biosciences's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Artelo Biosciences Earnings per Share (Diluted) Chart
Competitive Comparison of Artelo Biosciences's Earnings per Share (Diluted)
For the Biotechnology subindustry, Artelo Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's PE Ratio falls into.
Artelo Biosciences Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Artelo Biosciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Artelo Biosciences (NAS:ARTLW) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Artelo Biosciences Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of Artelo Biosciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Artelo Biosciences (Artelo Biosciences) Business Description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARTLW has been successfully added to your 